TOXICOLOGY AND APPLIED PHARMACOLOGY 8, 88-96 (1966)

Contribution of Aryl Groups to Toxic Interactions at Chemoreceptors: 3-Tropanol Phenylacetates and Their Hexahydro Derivatives as Toxic Agents

SEYMOUR L. FRIESS, L. J. REBER, AND R. C. DURANT
Division of Physical Biochemistry, Naval Medical Research Institute, Bethesda, Maryland 20014

Received January 8, 1965

Recent work with a series of monosubstituted compounds (Fig. 1) stemming from the phenylacetate esters I and I-\( \psi \) of the amino alcohols tropine (transoid) and \( \psi \)-tropine (cisoid) has shown that, in general, tropine aryl esters are more potent than their \( \psi \)-isomers in triggering a convulsion-paralysis-death syndrome in mice, and in evoking a concentration-dependent amplification of twitch response in the rat phrenic nerve-diaphragm preparation (Friess et al., 1964a,b). These actions are stereospecific with respect to cisoid or transoid disposition of the \( \text{--OCOCH}_2R \) residue on the tropane ring, and also very much dependent on the nature and position of single substituents (either electron-attracting or electron-donating) attached to the benzene ring of I or I-\( \psi \). Such observations, together with the curious finding (Friess et al., 1964b) that bulky ortho substitution in the aryl ring destroys the stereospecificity of the ester-receptor responses, are best accommodated by a model for receptor-ester binding which is multifunctional in character, with surface geometry of the receptor specifically tailored (or induced) to accommodate simultaneously the amine \( \text{>NHMe} \), ester \( \text{--OCO}-- \), and aryl ring structures.

1 From the Bureau of Medicine and Surgery, Navy Department, Research task MR 005.06-0010.01. The opinions in this paper are those of the authors and do not necessarily reflect the views of the Navy Department or the naval service at large.

2 Presented in part at the Fourth Annual Meeting of the Society of Toxicology, Williamsburg, Virginia, March 8-10, 1965.

Preceding Page Blank
However, at least one element of uncertainty in this model resides in the nature of the aryl group binding to the receptor surface, and particularly in the question of whether a charge-transfer process is invoked which imposes the necessity that the ring be aromatic. An answer to this question was sought directly by hydrogen saturation of the ring in I and I-ψ, yielding the cyclohexylacetate structures II and II-ψ with elimination of the conjugate unsaturation required for charge-transfer complex formation. The new saturated esters II and II-ψ have now been prepared and subjected to test on the same bioreceptor systems previously employed (intact animals, neuromuscular preparations, etc.) in observation of stereospecific effects produced by I and I-ψ, for pairwise comparisons of any differentiation in activity induced by saturation of the aryl ring. The somewhat surprising results of these comparisons form the basis of the present communication.

METHODS

Each of the new cyclohexylacetate esters II and II-ψ was synthesized by reflux of stoichiometric amounts of cyclohexylacetyl chloride and a given amino alcohol (tropine or ψ-tropine) in inert solvent, followed by isolation of the crude ester as its hydrochloride salt. The salts were repeatedly recrystallized to analytical purity in acetone-ether or chloroform-ether solvent mixtures, and submitted to elemental analyses, with the results summarized in Table I.

<table>
<thead>
<tr>
<th>Compound</th>
<th>Melting point (°C)</th>
<th>Analysis (%)</th>
<th>Element</th>
<th>Calculated</th>
<th>Found</th>
</tr>
</thead>
<tbody>
<tr>
<td>II-HCl</td>
<td>225</td>
<td></td>
<td>C</td>
<td>63.66</td>
<td>64.19</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>H</td>
<td>9.35</td>
<td>9.37</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>4.64</td>
<td>4.38</td>
</tr>
<tr>
<td>II-ψ-HCl</td>
<td>201</td>
<td></td>
<td>C</td>
<td>63.66</td>
<td>63.59</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>H</td>
<td>9.35</td>
<td>9.37</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>4.64</td>
<td>4.56</td>
</tr>
</tbody>
</table>

Freshly prepared solutions of the cyclohexyl ester hydrochlorides in isotonic saline or in the appropriate buffer (Ringer) media were employed in toxicity studies with intact mice and cats, in work on twitch potentiation and twitch blockade with the excised phrenic nerve-diaphragm preparation (PN-D) from the rat, and in studies of in vitro inhibitory potencies with respect to the purified esterase system acetylcholinesterase–acetylcholine (AcH-E–ACh). The animals, techniques, and protocols employed were identical in strain and content with those described in previous work (Friess et al., 1964a,b; Thron et al., 1963), to ensure full comparability of results obtained with the presently studied cyclohexyl esters II and II-ψ, and the previous data on action spectra of the corresponding phenylacetates I, I-ψ. The AcH-E enzyme preparation used for the esterase inhibitory studies was a highly purified sample derived from electric eel tissue, its natural substrate acetylcholine ion was supplied to form steady-state reaction mixtures from freshly prepared solutions of doubly recrystallized acetylcholine chloride, and the enzyme kinetics of reactions involving
enzyme-substrate-inhibitor mixtures were followed by the pH-stat techniques previously described (Friess et al., 1959).

RESULTS

Intravenous Toxicities in Mice and Cats

The new cyclohexylacetates II and II-ψ were tested as intravenously administered toxins in the NMRI strain of white mice (male), and in a mongrel population of well-nourished cats, with the results summarized in Table 2. These results are striking and in part quite unexpected, both from the standpoint of internal comparisons between the effects of II and II-ψ, and cross-comparisons with the corresponding aryl esters I and I-ψ (for which the mouse LD$_{50}$ data are also recalled in the Table).

It is seen first from Table 2 that the esters II and II-ψ obey the same general toxicity pattern found previously for the arylacetic esters, with prominent features of transient paralysis, tonic and clonic convulsions, respiratory impairment, and other complex manifestations of neuromuscular involvement. At the quantitative level of comparison, in mice, the first unexpected finding emerges in the observation that stereospecificity in toxic response is lost in the cyclohexyl derivatives: II and II-ψ are equivalent in LD$_{50}$ index of potency, within the spread of one standard deviation in the data. This finding is in strong contrast with all previous data from the aryl ester series (with the single exception of the class of bulky o-substituted aryl esters), in which the general rule has been a decided stereospecificity in toxic response with the invariant potency sequence: tropine ester > ψ-tropine ester (T > ψ-T). Further in the comparison of mouse toxicity data from Table 2, it is seen that hydrogenation of the phenyl ring in the potent T-series results in a very considerable drop in intrinsic toxicity (potency sequence I > II), whereas in the weaker ψ-T series saturation of the ring has only a marginal effect on potency (II-ψ ≥ I-ψ).

One finding in the cyclohexyl series which merits some emphasis, in contrast with the general aryl ester toxicity pattern, is the occurrence in the cat of a transient but marked impairment of visual function and some concomitant disorientation under the influence of the tropine ester II.

Effects on the Rat Phrenic Nerve-Diaphragm Preparation

The new cyclohexyl esters II and II-ψ afforded some surprises in their biphasic actions on the rat PN-D preparation, which turned out to be quite parallel to the unexpected facets of their toxic interactions in intact animals. The data are summarized in Table 3 in columns which deal, respectively, with the mode of electrical stimulation of the preparation (N = indirect stimulation via the phrenic nerve, M = directly via the muscle), the maximum degree of amplification produced by ester in isotonic N- and M-twitches at the 3-minute reference time, the concentration of agent yielding that maximum twitch potentiation, and the (higher) concentration of agent required to swamp out initial twitch amplification and produce 50% reduction from control twitch amplitude at the reference time post ester addition. Table 3 also reproduces reference data on twitch potentiation for the two phenyl esters I and I-ψ, for ease of comparison and contrast with results produced by the cyclohexyl esters II and II-ψ.
### TABLE 2

**Acute Intravenous Toxicities of Tropanol Esters in Mice and Cats**

<table>
<thead>
<tr>
<th>Compound</th>
<th>Mice</th>
<th>Cats</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>LD&lt;sub&gt;50&lt;/sub&gt; (mg/kg)</td>
<td>Toxic signs</td>
</tr>
<tr>
<td>H·HCl</td>
<td>36.0 ± 1.6</td>
<td>Immediate prostration, limbs extended, repetitive convulsive seizures, foreleg paralysis, loss of righting reflex. Later, broad-based stance, pawing at muzzle, hypersensitivity to auditory or tactile stimuli. Respiration impaired, frequent occurrence of tail curl, pronounced tendency to bite</td>
</tr>
<tr>
<td>H·HCl</td>
<td>34.0 ± 1.2</td>
<td>Signs as above. Additionally, respiration impaired by hiccoughs in large fraction of test animals, running and hopping, whole-body tremors, anoxia in later stages of repetitive convulsions</td>
</tr>
<tr>
<td>I·HCl</td>
<td>23.0 ± 0.8*</td>
<td></td>
</tr>
<tr>
<td>I·HCl</td>
<td>42.3 ± 1.6*</td>
<td></td>
</tr>
</tbody>
</table>

* Friess et al. (1964a).
Referring to the twitch potentiation column of Table 3, and just to the peak percentage subcolumn for the clearest mode of comparison, it is seen that the cyclohexyl esters are once again distinguished by a failure to show stereospecificity in evoking their weak potentiating responses from the PN-D preparation, curarized or uncurarized. Esters II and II-ψ appear to be virtually equipotent in their feeble amplification of N- and M-twitch responses, just as they are equipotent with respect to lethal strength in the intact mouse. Further, and in exact continuation of the analogy with regard to LD₅₀ levels in the mouse, the comparison of phenyl vs. cyclohexyl ester potentiating strength shows the stereospecific power sequence I > II in the stronger T-series, whereas in the weaker ψ-T series this stereospecificity vanishes into a rough power equivalence I-ψ ≈ II-ψ for the two weak potentiating agents.

In general with this excitable preparation, the effect of hydrogenating the phenyl group in I and I-ψ seems to be an abrupt diminution in the power of the T-isomer down to the potency level of the weaker ψ-T ester, with a simultaneous loss of the stereospecificity (T vs. ψ-T) inherent in the aryl esters.

**Effects on the Acetylcholinesterase-Acetylcholine System**

In view of the curious finding in the mouse toxicity and PN-D potentiation studies that hydrogenation of the phenyl group abruptly wipes out stereospecificity in biological response and reduces the absolute level of the response to that of the ψ-series, it became a matter of immediate interest to assay the new cyclohexyl esters for their inhibitory potencies vs. the in vitro AChE-ACh system operating at steady state. This esterase system has consistently shown a ψ-T > T ester stereospecificity in

### TABLE 3

**Effects of Tropanol Esters on Rat Phrenic Nerve-Diaphragm Preparation**

<table>
<thead>
<tr>
<th>Compound</th>
<th>Stimulation pathway</th>
<th>Concentration at peak (%)</th>
<th>Concentration at peak (M)</th>
<th>BC₅₀[^d] (M)</th>
</tr>
</thead>
<tbody>
<tr>
<td>II</td>
<td>N</td>
<td>122 ± 3</td>
<td>4.2 ± 0.2 × 10⁻⁴</td>
<td>9.2 ± 0.3 × 10⁻⁴</td>
</tr>
<tr>
<td></td>
<td>M</td>
<td>113 ± 5</td>
<td>3.2 ± 0.2 × 10⁻⁴</td>
<td>1.8 ± 0.1 × 10⁻³</td>
</tr>
<tr>
<td>II + d-tubo[^b]</td>
<td>M</td>
<td>130 ± 4</td>
<td>5.2 ± 0.2 × 10⁻⁴</td>
<td>2.2 ± 0.1 × 10⁻³</td>
</tr>
<tr>
<td>II-ψ</td>
<td>N</td>
<td>124 ± 5</td>
<td>2.2 ± 0.2 × 10⁻⁴</td>
<td>6.3 ± 0.2 × 10⁻⁴</td>
</tr>
<tr>
<td></td>
<td>M</td>
<td>114 ± 4</td>
<td>2.0 ± 0.2 × 10⁻⁴</td>
<td>1.2 ± 0.1 × 10⁻³</td>
</tr>
<tr>
<td>II-ψ + d-tubo[^b]</td>
<td>M</td>
<td>130 ± 6</td>
<td>3.3 ± 0.3 × 10⁻⁴</td>
<td>8.8 ± 0.3 × 10⁻⁴</td>
</tr>
<tr>
<td>I[^c]</td>
<td>N</td>
<td>142</td>
<td>5.4 × 10⁻⁴</td>
<td></td>
</tr>
<tr>
<td></td>
<td>M</td>
<td>142</td>
<td>5.8 × 10⁻⁴</td>
<td></td>
</tr>
<tr>
<td>I-ψ[^c]</td>
<td>N</td>
<td>120</td>
<td>5.6 × 10⁻⁴</td>
<td></td>
</tr>
<tr>
<td></td>
<td>M</td>
<td>125</td>
<td>5.5 × 10⁻⁴</td>
<td></td>
</tr>
</tbody>
</table>

[^a]: All readings of twitch height relative to control levels were made at 3.0 minutes after drug addition.

[^b]: Preparation curarized at the 1.0 × 10⁻⁵ M level of d-tubocurarine chloride.

[^c]: Data from the paper by Friess et al. (1964a).

[^d]: Concentration resulting in 50% reduction of twitch amplitude (or twitch tension) at the 3.0-minute time after ester addition.
inhibitory values for every pair of aryl ester isomers tested to date. The results of kinetic tests of the cyclohexylacetate esters II and II-ψ as reversible inhibitors of the esterase are briefly summarized in Table 4. The data in Table 4 are presented in the form of enzyme-inhibitor complex dissociation constants \( K_I \) calculated on both the competitive and noncompetitive bases by the equations of Wilson (1949). Constancy of a given inhibitory mechanism within a limited substrate concentration range, as indicated by braces around the data groupings of Table 4, is inferred from the constancy of calculated \( K_I \) values as the initial substrate concentration is varied.

<table>
<thead>
<tr>
<th>Compound</th>
<th>Initial ACh concentration (mM)</th>
<th>( K_I ) (comp)</th>
<th>( K_I ) (non-comp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>II</td>
<td>3.33</td>
<td>{ 3.55 ± 0.10 \times 10^{-5} }</td>
<td>5.73 ± 0.15 \times 10^{-4}</td>
</tr>
<tr>
<td></td>
<td>2.50</td>
<td>3.49 ± 0.08 \times 10^{-5}</td>
<td>4.31 ± 0.10 \times 10^{-4}</td>
</tr>
<tr>
<td></td>
<td>1.67</td>
<td>4.07 ± 0.14 \times 10^{-5}</td>
<td>3.49 ± 0.12 \times 10^{-4}</td>
</tr>
<tr>
<td>II-ψ</td>
<td>3.33</td>
<td>8.38 ± 0.16 \times 10^{-4}</td>
<td>{ 1.15 ± 0.03 \times 10^{-4} }</td>
</tr>
<tr>
<td></td>
<td>1.67</td>
<td>{ 1.35 ± 0.04 \times 10^{-4} }</td>
<td>{ 1.22 ± 0.04 \times 10^{-4} }</td>
</tr>
<tr>
<td>I</td>
<td>3.33</td>
<td>1.46 ± 0.06 \times 10^{-4}</td>
<td>2.36 ± 0.10 \times 10^{-3}</td>
</tr>
<tr>
<td></td>
<td>1.65</td>
<td>2.31 ± 0.10 \times 10^{-3}</td>
<td>2.31 ± 0.10 \times 10^{-3}</td>
</tr>
<tr>
<td>I-ψ</td>
<td>3.33</td>
<td>7.20 ± 0.13 \times 10^{-5}</td>
<td>1.16 ± 0.02 \times 10^{-3}</td>
</tr>
<tr>
<td></td>
<td>1.67</td>
<td>7.29 ± 0.22 \times 10^{-5}</td>
<td>1.16 ± 0.02 \times 10^{-3}</td>
</tr>
</tbody>
</table>

* At pH 7.40 and 25.21 ± 0.04°C.

With decreasing \( K_I \) values indicative of increasing inhibitory potency, and using the \( K_I \) (comp) values at the 3.33 mM level of ACh as the reference activity index, it is seen from Table 4 that this enzyme shows a sharply stereospecific preference for II-ψ over II as an inhibitor (by a strength factor of 4). This structural preference is in the normal steric sense for this enzyme (ψ-T > T). Further, the effect of hydrogenation of the phenyl ring is directly opposed to that seen in mice and with the PN-D preparation; saturation of the ring in each series leads to an increase in AChE-inhibitory potency (strength sequences: II > I by a factor of 4; II-ψ > I-ψ by a factor of 8.6). A further item of interest from Table 4 stems from the similarity in the pairs II, II-ψ and I, I-ψ with respect to failure to adhere to a single inhibitory mechanism. It is seen that both the cyclohexylacetates and the phenylacetates undergo a change in inhibitory mechanism on shift from one stereochemical series (T) to the other (ψ-T).

**DISCUSSION**

The present results offer an exceptional demonstration of the role played by an aryl group in adding to effective interactions at biological chemoreceptors in tissues. The essential elements of interacting structure in the triggering molecules I, I-ψ, II and II-ψ group into the categories (a), (b) and (c), in which (a) and (b) are frozen geometrically (Fig. 2) into either T or ψ-T configurational relationship, and
in which T-geometry is favored by tissue receptors responsive to aryl esters. Now, the extent to which aromaticity and/or planarity in structural element (c) aids the total interaction process in tissue leading to receptor-controlled responses seems to depend intimately on the nature of the receptor involved. With receptors involved in the paralysis-convulsion toxicity syndrome in mice, and with those controlling twitch potentiation in the rat PN-D preparation, saturation in the phenyl ring of T-series esters results in an abrupt decrease in trigger potency (I vs. II), and therefore presumably a corresponding decrease in the contribution made by structure element (c) to receptor interaction processes. This decrease in potency is only observed when structural elements (a) and (b) are in the favored transoid (T-series) relationship with respect to one another, and the decrease at most is only down to the strength level characteristic of the aryl ester with the unfavored cisoid relationship between (a) and (b).

![Diagram](image)

**Fig. 2.** Elements of structure affecting ester interaction with receptor sites.

Therefore, it would appear that the planar aryl group at (c) does indeed contribute to the total interaction potency of the T-series phenyl ester I at these particular tissue receptors, and that the structural transformation phenyl → cyclohexyl wipes out this increment of potency. Further, the fact that this increment occurs only in the stereochemically favored T-series and not with y-T isomers implies that the drug receptors triggered by these esters show a geometric specificity that is at least threefold. Only when (a) and (b) are bound in transoid fashion can the aryl group be brought into proper juxtaposition with the receptor surface for the additional interaction (c) as the third mode of effective contact. The net demonstration of selectivity on the part of (central) receptors in the mouse and peripheral synaptic receptors of the rat, then, is a show of enhanced susceptibility to the action of I (modes (a), (b) and (c) all operative), and a lesser (and constant) level of response to esters I-y, II and II-y in which only modes (a) and (b) contribute to interaction with receptor surfaces.

There is also a reciprocal implication in the potency equivalence II = II-y with these two classes of receptors. Unless an aryl group is present per se to add its increment of interaction at the receptor surface, the receptor loses its stereoselectivity with respect to discrimination between cisoid and transoid ester configurations at
ARYL ESTER TOXICITY

(a)-(b), and lumps all bipolar modes of attachment into one activity level. But when mode (c) is brought to bear, selectivity in terms of favoring the transoid mode at (a)-(b) is apparent. From this point of view, stereospecificity in these tissue responses is only unlocked by the necessary condition that a phenyl (or substituted phenyl) group add increment (c) to the interaction picture.

On shifting to the class of "receptors" exemplified by the active site region of the enzyme AChE, however, a radically different ester interaction picture from that drawn above emerges. The inhibitory strength sequences II·ψ > II and I·ψ > I (Table 4) clearly show the superiority of cisoid structure over transoid configuration in AChE inhibition, independent of any requirement for the presence of a phenyl group in the inhibitor. Indeed, in the full sequence of four esters in Table 4, the intrinsic inhibitory potency runs in the series: II·ψ > II > I·ψ > I. Therefore the cyclohexyl derivatives are both more potent than their aromatic phenyl congeners, and no phenyl group is required as a necessary condition for evocation of T vs. ψ-T stereospecificity. Further, the comparative findings that (1) the specificity pattern for AChE inhibition is exactly inverted from that shown by the mouse and rat chemo-receptors, and (2) the esterase shows no requirement for phenyl group substitu-

![Diagram](https://via.placeholder.com/150)

**Fig. 3.** Potential charge-transfer complex formation during ester-receptor interaction.

...tion as a prerequisite to stereospecificity whereas the animal tissue receptors do, both militate against the possibility that this esterase moiety is an integral part of the animal chemoreceptor systems studied.

The observation that the cyclohexyl esters are respectively stronger than their phenyl analogs in inhibition of the AChE-ACh system *in vitro* is also subject to one further line of interpretation. If the primary enzyme-inhibitor binding is of the binary type involving simultaneous interactions at anionic and esteratic sites of the catalytic locus (Nachmansohn and Wilson, 1951), then any further diversionary modes of ester attachment to the catalytic surface could act to the detriment of the primary binding modes. In particular, if phenyl groups are bound at a third point on or near the catalytic locus and cyclohexyl groups are not, this extra binding could...
well disrupt the precise positioning and interaction at the anionic-esteratic region (via > NHMe and —OCO— functions in the ester) and produce the drop to weaker inhibition characteristic of the phenyl esters I and I-ψ. One final point of interest that attaches to the finding of a phenyl group requirement [mode (c)] for enhanced toxicities in the mouse and potentiating activity at the rat PN-D synapse centers about possible mechanisms for modes of interaction in the tissue milieu. Since the net steric bulk of a phenyl residue is not too different from that of its hexahydro derivative, it would seem that planarity and conjugate unsaturation in the phenyl ring hold the key to a feasible mechanism underlying the mode (c) contribution to ester-receptor interaction. These two features of aryl group structure, of course, are precisely suited to the general phenomenon of complex formation via a charge transfer process, in which the phenyl group acts as an electron sink. Hence, a charge-transfer complex of the type shown in Fig. 3 might well account for the added increment of interaction effectiveness afforded by aromaticity in tropine esters based on structure I.

SUMMARY

The new cyclohexylacetate esters of tropine and ψ-tropine have been studied as toxins by the intravenous route in intact mice and cats, as twitch-potentiating agents on the rat phrenic nerve-diaphragm preparation, and as inhibitors of the acetylcholinesterase-acetylcholine system. In sharp contrast with their phenyl ester analogs, the cyclohexyl esters show an abrupt loss of capability to evoke stereospecific responses from chemoreceptor systems in the rat and mouse tissues, and yet display absolute levels of activity equivalent to those of the phenyl ester in the weaker ψ-tropine series. With the acetylcholinesterase system studied as a key nerve enzyme, the cyclohexyl esters show exactly inverted behavior in the sense that they are highly stereospecific with respect to their inhibitory potencies (ψ-tropine > tropine ester), and each cyclohexyl ester is significantly stronger as a reversible inhibitor than its phenyl analog.

These results are interpreted in terms of possible modes of functional interaction between these esters and the chemoreceptors controlling the responses of the tissue and enzyme systems studied.

ACKNOWLEDGMENT

We are indebted to F. J. Fash, HMC, USN, for his technical assistance in certain phases of this work, and to the Microanalytical Laboratories, National Institute of Arthritis and Metabolic Diseases, Bethesda, Maryland, for the elemental microanalyses.

REFERENCES


CONTRIBUTION OF ARYL GROUPS TO TOXIC INTERACTIONS AT CHEMORECEPTORS. 3-TROPANOL PHENYLACETATES AND THEIR HEXAHYDRO DERIVATIVES AS TOXIC AGENTS

The new cyclohexylacetate esters of tropine and \( \psi \)-tropine have been studied as toxins by the intravenous route in intact mice and cats, as twitch-potentiating agents on the rat phrenic nerve-diaphragm preparation, and as inhibitors of the acetylcholinesterase-acetylcholine system. In sharp contrast with their phenyl ester analogs, the cyclohexyl esters showed abrupt loss of capability to evoke stereospecific responses from chemoreceptor systems in the rat and mouse tissues, and yet display absolute levels of activity equivalent to those of the phenyl ester in the weaker \( \psi \)-tropine series. With the acetylcholinesterase system studied as a key nerve enzyme, the cyclohexyl esters show exactly inverted behavior in the sense that they are highly stereospecific with respect to their inhibitory potencies (\( \psi \)-tropine > tropine ester), and each cyclohexyl ester is significantly stronger as a reversible inhibitor than its phenyl analog. (U)

The results are interpreted in terms of possible modes of functional interaction between these esters and the chemoreceptors controlling the responses of the tissue and enzyme systems studied. (U)
### Toxic Interactions
- Chemoreceptors
- 3-Tropanol phenylacetates
- Charge-transfer process
- Phrenic nerve-diaphragm preparation
- Sterospecific effects
- Neuromuscular preparations
- Twitch amplification
- Enzyme inhibitor dissociation constants
- Biological chemoreceptors
- Peripheral synaptic receptors
- Toxins
- Sterospecific responses

### INSTRUCTIONS

1. **ORIGINATING ACTIVITY:** Enter the name and address of the contractor, subcontractor, grantee, Department of Defense activity or other organization (corporate author) issuing the report.

2a. **REPORT SECURITY CLASSIFICATION:** Enter the overall security classification of the report. Indicate whether "Restricted Data" is included. Marking is to be in accordance with appropriate security regulations.

2b. **GROUP:** Automatic downgrading is specified in DoD Directive 5200.10 and Armed Forces Industrial Manual. Enter the group number. Also, when applicable, show that optional markings have been used for Group 3 and Group 4 as authorized.

3. **REPORT TITLE:** Enter the complete report title in all capital letters. Titles in all cases should be unclassified. If a meaningful title cannot be selected without classification, show title classification in all capitals in parenthesis immediately following the title.

4. **DESCRIPTIVE NOTES:** If appropriate, enter the type of report, e.g., interim, progress, summary, annual, or final. Give the inclusive dates when a specific reporting period is covered.

5. **AUTHOR(S):** Enter the name(s) of author(s) as shown on or in the report. Enter last name, first name, middle initial. If military, show rank and branch of service. The name of the principal author is an absolute minimum requirement.

6. **REPORT DATE:** Enter the date of the report as day, month, year; or month, year. If more than one date appears on the report, use date of publication.

7a. **TOTAL NUMBER OF PAGES:** The total page count should follow normal pagination procedures, i.e., enter the number of pages containing information.

7b. **NUMBER OF REFERENCES:** Enter the total number of references cited in the report.

8a. **CONTRACT OR GRANT NUMBER:** If appropriate, enter the applicable number of the contract or grant under which the report was written.

8b. **& 8d. PROJECT NUMBER:** Enter the appropriate military department identification, such as project number, subproject number, system numbers, task number, etc.

9a. **ORIGINATOR'S REPORT NUMBER(S):** Enter the official report number by which the document will be identified and controlled by the originating activity. This number must be unique to this report.

9b. **OTHER REPORT NUMBER(S):** If the report has been assigned any other report numbers (either by the originator or by the sponsor), also enter this number(s).

10. **AVAILABILITY/LIMITATION NOTICES:** Enter any limitations on further dissemination of the report, other than those imposed by security classification, using standard statements such as:

   1. "Qualified requesters may obtain copies of this report from DDC."
   2. "Foreign announcement and dissemination of this report by DDC is not authorized."
   3. "U.S. Government agencies may obtain copies of this report directly from DDC. Other qualified DDC users shall request through ."
   4. "U.S. military agencies may obtain copies of this report directly from DDC. Other qualified users shall request through ."
   5. "All distribution of this report is controlled. Qualified DDC users shall request through ."

If the report has been furnished to the Office of Technical Services, Department of Commerce, for sale to the public, indicate this fact and enter the price, if known.

11. **SUPPLEMENTARY NOTES:** Use for additional explanatory notes.

12. **SPONSORING MILITARY ACTIVITY:** Enter the name of the departmental project office or laboratory sponsoring (paying for) the research and development. Include address.

13. **ABSTRACT:** Enter an abstract giving a brief and factual summary of the document indicative of the report, even though it may also appear elsewhere in the body of the technical report. If additional space is required, a continuation sheet shall be attached.

   It is highly desirable that the abstract of classified reports be unclassified. Each paragraph of the abstract shall end with an indication of the military security classification of the information in the paragraph, represented as (TS); (S); (C); or (U).

   There is no limitation on the length of the abstract. However, the suggested length is from 150 to 225 words.

14. **KEY WORDS:** Key words are technically meaningful terms or short phrases that characterize a report and may be used as index entries for cataloging the report. Key words must be selected so that no security classification is required. Identifiers, such as equipment model designation, trade name, military project code, geographic location, may be used as key words but will be followed by an indication of technical context. The assignment of links, rules, and weights is optional.